색전 방지 기기 시장 : 시장 규모, 점유율, 동향 분석(2026-2032년)

Global Embolic Protection Device Market Report

The global embolic protection device market was valued at $134 million in 2025. Over the forecast period, the market is expected to grow at a CAGR of 1.1% to reach $144 million by 2032.

• The full report suite on the global market for embolic protection devices, or EPDs, covers seven geographical regions: North America, Latin America, Western Europe, Central and Eastern Europe, the Middle East, Asia-Pacific and Africa. For each region, the report provides market valuation, unit analysis and average selling price data, while also extending projections through 2032 to provide a clear and forward-looking view of market performance. This description follows the same overall structure and best-practice sequence used in the attached example document, adapted to the specific clinical and commercial dynamics of the EPD market .

This report provides detailed analysis of the global EPD market, including unit sales, procedure numbers, average selling prices, market size, growth trends, market shares and forecasts through 2032, with historical data to 2022. It also includes recent mergers and acquisitions, company profiles, product portfolios and competitive analysis of the leading companies across major regional markets.

The market is being shaped by a mix of procedural growth and practical limitations. On the positive side, the use of EPDs in lower-limb atherectomy and other high-risk peripheral procedures continues to support unit demand. At the same time, improving imaging and navigation technologies are helping physicians deploy these devices more effectively. On the limiting side, the popularity of carotid endarterectomy, lack of broad physician training in endovascular workflows and the bundling of EPDs with stents continue to restrain market value growth.

Overall, the global embolic protection device market is stable but modest in growth. It remains relevant in selected procedures and patient populations, but broader adoption depends on physician training, reimbursement environment, procedure mix and the continued development of devices that improve ease of use and clinical confidence.

Market Overview

The global embolic protection device market includes devices used during endovascular procedures to prevent embolic debris from traveling downstream and causing complications such as stroke, ischemia or distal vessel blockage. These devices are especially relevant in vascular territories where plaque disruption or thrombotic material can create significant clinical risk during intervention.

Historically, the strongest role for EPDs has been in carotid artery stenting. In carotid procedures, embolic debris can travel to the brain, so protection during the intervention is an important safety consideration. Over time, EPD use has also expanded into selected lower-limb atherectomy procedures and other cases where lesion disruption may release particulate material. This has helped broaden the clinical footprint of the category, although the market remains centered around a relatively small number of indications.

The EPD market is highly tied to the procedure categories in which it is used. It does not create demand independently. Instead, it depends on the volume and growth of carotid stenting, lower-limb atherectomy, selected renal or peripheral interventions and, in some portfolios, cerebral protection related to structural heart procedures. Because of this, the market grows in line with changes in physician preference, clinical guidelines and the overall adoption of protected endovascular treatment.

The market is also evolving with broader technology development in vascular intervention. Imaging and navigation tools are improving how operators assess anatomy, position devices and manage procedural risk. This trend is helping support next-generation EPD development, especially in more complex procedures where real-time vessel assessment can improve decision-making and reduce complications.

Overall, the global EPD market remains a focused safety-oriented category. Its future depends less on mass procedural expansion and more on how physicians balance risk, workflow complexity, reimbursement and the perceived value of embolic protection in selected intervention types.

Market Drivers

Lower-Limb Atherectomy Procedures

One of the main drivers in the global EPD market is the use of embolic protection devices in lower-limb atherectomy procedures. After carotid stenting, this is one of the most frequent use settings for EPDs. Atherectomy procedures can release particulate debris, especially in complex peripheral arterial disease cases, which makes embolic protection relevant in selected interventions.

As the global population ages, the number of procedures performed to treat peripheral arterial disease is expected to rise. This includes atherectomy procedures in lower-limb vessels, where disease burden, calcification and lesion complexity can increase the risk of distal embolization. As these procedure volumes grow, demand for EPDs used in lower-limb cases is expected to rise as well. This is one of the clearest procedural supports for unit growth in the category.

Aging Population and PAD Burden

A broader driver behind the EPD market is the rising burden of peripheral vascular disease and related comorbidities. Older patients are more likely to present with plaque-heavy, calcified or otherwise complex lesions that may benefit from embolic protection when treated endovascularly. Since the market is closely tied to these more advanced procedures, the aging patient base indirectly supports EPD demand.

This trend is especially relevant in peripheral intervention because patients with PAD often also have diabetes, renal disease and other risk factors that make treatment more complicated. As the complexity of cases rises, so does the procedural logic for embolic protection in selected interventions.

High Reimbursement in Germany

Germany has historically been an important driver for parts of the EPD market due to relatively high reimbursement rates in related intervention categories. While this has not applied uniformly across all markets, the German market in particular has benefited from stronger economic support in thrombectomy-linked or related procedural areas. This has helped support use of more advanced endovascular devices in settings where hospitals otherwise might be more cost constrained.

Although reimbursement structures are changing, the historical strength of reimbursement in Germany has been one factor that supported acquisition and use of these devices. In markets without similar support, hospitals often rely more heavily on private settings or selectively limit device use. This makes the German experience especially relevant in understanding where the market has seen better traction.

Market Limiters

Popularity of Endarterectomy

The most important limiter in the global EPD market is the continued popularity of carotid endarterectomy. Although carotid stenting adopted stronger EPD requirements after data such as the CREST trial influenced practice patterns, endarterectomy remains the preferred treatment approach for many physicians worldwide when addressing carotid artery blockages.

This preference matters because carotid stenting is one of the main procedure categories that drives EPD use. If physicians continue favoring open surgical treatment due to lower rates of serious adverse events in the early post-procedure period, then EPD demand remains constrained. In other words, one of the category's core procedural bases grows more slowly when endarterectomy stays dominant.

Lack of Physician Training

Lack of physician training is another major limiter. Neurologists and vascular surgeons are not always trained primarily in endovascular technique, and embolic protection can make a procedure more technically demanding because the physician must manage both the treatment device and the protection device. This added complexity can discourage broader use, especially in lower-volume settings or in regions where endovascular specialization is less developed.

This training gap has a direct effect on penetration. Even if physicians understand the theoretical value of embolic protection, they may be slower to adopt a workflow that adds steps and requires greater procedural confidence. This delays broader uptake and contributes to the market's relatively modest growth profile.

Bundling and Discounting

Bundling is also a significant market limiter. In many markets, companies bundle sales of embolic protection devices with carotid stents or other related products. While this can help place devices and support account relationships, it also encourages heavy discounting and places downward pressure on EPD market value.

This is especially important in countries where the carotid stenting market is less developed. In those environments, suppliers may use aggressive pricing and packaging strategies to protect broader portfolio positions. That supports unit use in some cases, but it can cap revenue growth and keep average selling prices under pressure.

Market Coverage and Data Scope

Quantitative Coverage

Market size, market shares, market forecasts, market growth rates, units sold and average selling prices.

Qualitative Coverage

Market drivers and limiters, growth trends, recent mergers and acquisitions, company profiles, product portfolios and leading competitors.

Time Frame

Base year 2025, historical data to 2022 and forecasts through 2032.

Regional Coverage

North America, Latin America, Western Europe, Central and Eastern Europe, the Middle East, Asia-Pacific and Africa.

Data Types Included

Unit sales, average selling prices, procedure numbers, market size and growth trends.

This report is structured to support strategic planning and competitive benchmarking by combining procedure-linked market sizing with pricing analysis and practical clinical context.

Markets Covered and Segmentation

• The report covers the Global Embolic Protection Device Market, further segmented by device type into:

Carotid Embolic Protection Devices

These devices are used primarily in carotid artery stenting procedures to reduce the risk of cerebral embolization and stroke during intervention.

Renal Embolic Protection Devices

These devices are used in selected renal vascular procedures where protection from embolic debris is clinically important.

Lower-Limb Embolic Protection Devices

These devices are used in selected peripheral procedures, especially lower-limb atherectomy, where particulate debris can be released during lesion treatment.

Each segment is analyzed by unit sales, average selling prices and total market value, with forecasts through 2032 and historical data to 2022. This segmentation reflects the main vascular territories in which embolic protection plays a procedural role.

Competitive Analysis

Medtronic entered the U.S. embolic protection device market through its acquisition of Covidien in January 2015, which gave it access to the SpiderFX device that had come through ev3. SpiderFX features a radiopaque band to assist with placement and a stable braided filter design. It holds approvals for carotid, lower-limb and saphenous vein grafting indications. In 2025, Medtronic led the alternative EPD market, and SpiderFX remained the only standalone EPD approved specifically for lower-limb procedures. This gives the company a unique and defensible position in one of the most important non-carotid uses of embolic protection.

Abbott Vascular entered the market in 2006 through the acquisition of Guidant's embolic protection and carotid stent platforms, becoming the first company to offer a carotid-approved EPD. That early presence, combined with physician familiarity, helped support Abbott's durable position in the market. Product evolution also reinforced this role. The Emboshield NAV6 system introduced improved basket design, retrieval functionality and proprietary BareWire technology for more independent wire movement. Abbott also expanded the indication of its RX Accunet EPD, supporting continued relevance in carotid intervention.

Boston Scientific remains another important competitor. Its FilterWire EZ device is used in carotid and saphenous vein graft indications and is designed to provide embolic protection across a range of vessel sizes while maintaining blood flow through a uniform micro-pore filter. Boston Scientific also strengthened its broader protection portfolio through the acquisition of Claret Medical in 2018, which added the Sentinel cerebral protection system for transcatheter aortic valve replacement procedures. By bundling Sentinel with its TAVR product line, Boston Scientific improved portfolio synergy and strengthened its competitive position in protection-related interventions.

Overall, the competitive landscape is shaped by procedure-specific approvals, device familiarity, bundling strategy and the ability to integrate embolic protection into broader vascular and structural heart portfolios.

Technology and Practice Trends

One of the clearest trends in the EPD market is the integration of advanced imaging and navigation tools into endovascular workflows. Better real-time visualization is helping operators assess anatomy, plaque burden and device position more accurately during intervention.

This trend supports more precise embolic protection and can improve operator confidence in more complex cases. Technologies such as intravascular ultrasound and optical coherence tomography are increasingly relevant in this context.

Another important trend is the continued role of lower-limb protection in atherectomy. As atherectomy expands in selected peripheral disease cases, EPD use in lower-limb procedures remains a meaningful area of focus.

The market is also increasingly shaped by portfolio bundling. Rather than competing as isolated devices, EPDs are often positioned alongside stents, atherectomy systems or structural heart products, which affects both pricing and account penetration.

Geography

This report provides global coverage across North America, Europe, Asia-Pacific, Latin America, the Middle East, and Africa.

66 pages of detailed market analysis, segmentation and forecast data.

Methodology Appendix and Acronym Glossary.

Why This Report

Where are the most stable opportunities in the global embolic protection device market through 2032?

How are carotid, renal and lower-limb EPD segments expected to perform across regions?

What role do lower-limb atherectomy growth and physician training play in future unit demand?

How do endarterectomy preference, bundling and reimbursement conditions limit market expansion?

Which competitors hold the strongest positions in carotid and lower-limb embolic protection, and how are they differentiating their products?

How are imaging and navigation advances shaping the next phase of embolic protection device development?

The Global Embolic Protection Device Market Report from iData Research answers these questions with detailed market sizing, pricing analysis, segmentation and competitive intelligence. Use it to benchmark competitors, understand procedural demand and support strategy in a specialized but clinically important vascular device market.

TABLE OF CONTENT

List Of Figures

List Of Charts

Research Methodology

• Step 1: Project Initiation & Team Selection
• Step 2: Prepare Data Systems And Perform Secondary Research
• Step 3: Preparation For Interviews & Questionnaire Design
• Step 4: Performing Primary Research
• Step 5: Research Analysis: Establishing Baseline Estimates
• Step 6: Market Forecast And Analysis
• Step 7: Identify Strategic Opportunities
• Step 8: Final Review And Market Release
• Step 9: Customer Feedback And Market Monitoring

Impact Of Global Tariffs

Embolic Protection Device Market

• 12.1 Executive Summary
  • 12.1.1 Global Embolic Protection Device Market Overview
  • 12.1.2 Competitive Analysis
  • 12.1.3 Procedures Included
  • 12.1.4 Markets Included
  • 12.1.5 Regions Included
• 12.2 Introduction
  • 12.2.1 Protection Mechanism
    • 12.2.1.1 Filter Basket
    • 12.2.1.2 Distal Balloon Occlusion
    • 12.2.1.3 Flow Redirection
• 12.3 Procedure Numbers
• 12.4 Market Overview
  • 12.4.1 By Segment
  • 12.4.2 By Region
• 12.5 Market Analysis And Forecast
  • 12.5.1 Total Embolic Protection Device Market
  • 12.5.2 Carotid Epd Market
  • 12.5.3 Renal Epd Market
  • 12.5.4 Lower-Limb Epd Market
• 12.6 Drivers And Limiters
  • 12.6.1 Market Drivers
  • 12.6.2 Market Limiters
• 12.7 Competitive Market Share Analysis

Abbreviations